ELTX

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

Wall Street analysts forecast ELTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELTX is 15.50 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Elicio Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Elicio Therapeutics Inc. EPS for the last quarter amounts to -0.60 USD, decreased -56.83 % YoY.

Elicio Therapeutics Inc (ELTX) has 32 emplpoyees as of December 15 2025.

Today ELTX has the market capitalization of 143.15M USD.